Square Pharmaceuticals PLC. (DSE:SQURPHARMA)
Bangladesh
· Delayed Price · Currency is BDT 209.80
+2.50 (1.21%)
At close: Mar 9, 2026
DSE:SQURPHARMA Cash Flow Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Net Income | 25,948 | 23,968 | 20,926 | 18,980 | 18,157 | 15,947 | Upgrade
|
| Depreciation & Amortization | 2,200 | 2,201 | 2,319 | 2,310 | 1,835 | 1,882 | Upgrade
|
| Loss (Gain) From Sale of Assets | -24.02 | -29.06 | 208 | 79.8 | -53.49 | -34.43 | Upgrade
|
| Loss (Gain) From Sale of Investments | 89.01 | - | - | - | - | -177.04 | Upgrade
|
| Loss (Gain) on Equity Investments | -2,987 | -3,194 | -2,595 | -2,523 | -2,011 | -1,291 | Upgrade
|
| Other Operating Activities | -5,577 | -5,647 | -4,927 | -4,654 | -3,838 | -3,330 | Upgrade
|
| Change in Accounts Receivable | 286.43 | 314.83 | 869.7 | -1,262 | -522.93 | -115.84 | Upgrade
|
| Change in Inventory | 1,680 | -477.05 | -354.95 | -4,177 | -968.71 | -1,558 | Upgrade
|
| Change in Accounts Payable | -39.97 | -80.58 | 453.67 | 375.77 | -40.18 | 127.76 | Upgrade
|
| Change in Income Taxes | - | - | - | -555.41 | 338.83 | -405.36 | Upgrade
|
| Change in Other Net Operating Assets | 53.86 | 245.58 | 1,629 | -29.96 | -22.88 | -69.56 | Upgrade
|
| Operating Cash Flow | 21,629 | 17,302 | 18,529 | 8,546 | 12,875 | 10,976 | Upgrade
|
| Operating Cash Flow Growth | 64.81% | -6.62% | 116.82% | -33.63% | 17.29% | 2.01% | Upgrade
|
| Capital Expenditures | -6,597 | -6,177 | -4,181 | -2,861 | -6,183 | -3,798 | Upgrade
|
| Sale of Property, Plant & Equipment | 77.86 | 84.14 | 97.44 | 78.33 | 130.7 | 80.13 | Upgrade
|
| Investment in Securities | -8,982 | -4,124 | -7,221 | -858.01 | -1,416 | -798.2 | Upgrade
|
| Other Investing Activities | 6,006 | 6,320 | 4,256 | 4,428 | 3,499 | 3,239 | Upgrade
|
| Investing Cash Flow | -9,495 | -3,897 | -7,049 | 787.69 | -3,970 | 3,607 | Upgrade
|
| Long-Term Debt Issued | - | - | - | 72.7 | 1,811 | 103.71 | Upgrade
|
| Total Debt Issued | - | - | - | 72.7 | 1,811 | 103.71 | Upgrade
|
| Long-Term Debt Repaid | - | -603.58 | -557.89 | - | - | - | Upgrade
|
| Total Debt Repaid | -618.17 | -603.58 | -557.89 | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -618.17 | -603.58 | -557.89 | 72.7 | 1,811 | 103.71 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | - | 0.5 | Upgrade
|
| Common Dividends Paid | -9,715 | -9,709 | -9,275 | -8,803 | -5,302 | -3,923 | Upgrade
|
| Other Financing Activities | - | - | - | -32.23 | -262.5 | - | Upgrade
|
| Financing Cash Flow | -10,333 | -10,313 | -9,833 | -8,762 | -3,754 | -3,819 | Upgrade
|
| Foreign Exchange Rate Adjustments | 111.78 | 290.81 | 271.89 | 560.97 | 447.1 | 35.61 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | - | - | - | -0 | Upgrade
|
| Net Cash Flow | 1,912 | 3,383 | 1,919 | 1,132 | 5,598 | 10,800 | Upgrade
|
| Free Cash Flow | 15,032 | 11,125 | 14,348 | 5,685 | 6,692 | 7,178 | Upgrade
|
| Free Cash Flow Growth | 137.48% | -22.46% | 152.37% | -15.04% | -6.78% | -17.66% | Upgrade
|
| Free Cash Flow Margin | 18.34% | 14.58% | 20.47% | 9.37% | 11.62% | 14.16% | Upgrade
|
| Free Cash Flow Per Share | 16.96 | 12.55 | 16.18 | 6.41 | 7.55 | 8.10 | Upgrade
|
| Cash Interest Paid | 157.05 | 226.55 | 246.14 | 87.68 | 0.03 | 0.01 | Upgrade
|
| Cash Income Tax Paid | 4,122 | 4,052 | 4,320 | 5,127 | 4,494 | 4,595 | Upgrade
|
| Levered Free Cash Flow | 11,864 | 8,567 | 11,476 | 2,948 | 4,800 | 10,672 | Upgrade
|
| Unlevered Free Cash Flow | 11,955 | 8,702 | 11,629 | 3,022 | 4,800 | 10,672 | Upgrade
|
| Change in Working Capital | 1,980 | 2.78 | 2,598 | -5,648 | -1,216 | -2,021 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.